CLINICAL TRIALS PROFILE FOR OCRIPLASMIN
✉ Email this page to a colleague
All Clinical Trials for ocriplasmin
| Trial ID | Title | Status | Sponsor | Phase | Start Date | Summary |
|---|---|---|---|---|---|---|
| NCT00412451 ↗ | A Multicenter Study to Compare Multiple Doses of Intravitreal Microplasmin Versus Sham Injection for Treatment of Patients With Diabetic Macular Edema (DME) | Completed | ThromboGenics | Phase 2 | 2006-12-01 | A multicenter study to compare multiple doses of intravitreal microplasmin for non-surgical PVD induction for treatment of patients with DME. |
| NCT00435539 ↗ | A Study to Compare Multiple Doses Intravitreal Microplasmin for Treatment of Patients With Vitreomacular Traction (MIVI-IIt) | Completed | ThromboGenics | Phase 2 | 2007-02-01 | A multicenter study to compare multiple doses of intravitreal microplasmin for non-surgical PVD induction for treatment of patients with vitreomacular traction. |
| NCT00913744 ↗ | Safety and Efficacy Study of Intravitreal Ocriplasmin in Subjects With AMD With Focal Vitreomacular Adhesion | Completed | ThromboGenics | Phase 2 | 2010-01-01 | This study will evaluate the safety and efficacy of Ocriplasmin intravitreal injection, in subjects diagnosed with exudative AMD with focal vitreomacular adhesion. Ultimately, it is believed that intravitreal ocriplasmin may offer physicians a safe agent for pharmacologic vitreolysis and nonsurgical resolution of focal vitreomacular adhesion in AMD subjects where this adhesion may be causally associated with worse prognosis). |
| NCT00986362 ↗ | Clinical Trial of Intravitreal Microplasmin in Infants and Children Scheduled for Vitrectomy | Completed | ThromboGenics | Phase 2 | 2010-02-01 | To evaluate the safety and preliminary efficacy of intravitreal microplasmin as an adjunct to conventional vitrectomy for the treatment of pediatric patients. |
| NCT01159665 ↗ | The Purpose of This Study is to Evaluate the Pharmacokinetic Properties of Intravitreal Ocriplasmin Prior to Planned Primary Pars Plana Vitrectomy (PPV) | Completed | ThromboGenics | Phase 2 | 2010-07-01 | To evaluate the pharmacokinetic properties of intravitreal ocriplasmin 125 µg dose when administered at different time-points prior to planned primary pars plana vitrectomy (PPV) |
| NCT01287988 ↗ | Follow-up Study to Assess Visual Function in Subset of Patients Who Have Previously Participated in the TG-MV-006 and TG-MV-007 Ocriplasmin Studies | Completed | ThromboGenics | 2011-05-01 | The primary objective of this study is to assess visual function in up to 44 patients who have previously participated in either of the placebo controlled, ocriplasmin Phase III studies (TG-MV-006 or TG-MV-007). | |
| NCT01429441 ↗ | Ocriplasmin for Treatment for Symptomatic Vitreomacular Adhesion Including Macular Hole | Completed | ThromboGenics | Phase 3 | 2011-10-01 | The purpose of this study is to evaluate the treatment of symptomatic vitreomacular adhesion / (VMT) including macular hole with ocriplasmin. |
| >Trial ID | >Title | >Status | >Sponsor | >Phase | >Start Date | >Summary |
Clinical Trial Conditions for ocriplasmin
Condition Name
Clinical Trial Locations for ocriplasmin
Trials by Country
Clinical Trial Progress for ocriplasmin
Clinical Trial Phase
Clinical Trial Sponsors for ocriplasmin
Sponsor Name
